The Pistoia Alliance, a global, non-business entity that works to lower blockades to breakthroughs in life sciences research and development, has expanded its Blockchain project to include data sharing, data identity, and data integrity. Founded in 2007, with representatives from renowned pharmaceutical industry companies that include Pfizer, Novartis, and GSK, the Pistoia Alliance was developed to support incorporate new technology to help in the companies’ respective R&D fields.
According to the Pistoia Alliance, its latest project will focus on the utilization of Blockchain to authenticate sources in spotting data, to ensure data integrity, and to improve sharing between the organizations. Earlier to its foray into Blockchain-based data management, Pistoia focused on educating the medical industry on the rising technology. As noted by Pistoia, a recent survey found that access to skilled human resources and realizing of the technology are the prime roadblocks to Blockchain’s adoption. Additionally, the same survey reported that one-fifth of respondents do not consider Blockchain adds value beyond a standard database. The President of the Pistoia Alliance, Steve Arlington stated that several industries are still at the discussion phase of Blockchain. He further said that his team wants to go beyond this and take action which actively helps members and leads to concrete results that will benefit R&D, fuel breakthroughs and support the exploration of new treatments.
In order to research and development, Distributed Ledger Technology (DLT) has been deployed across the healthcare industry to make medical data more shareable and more secure. In the same context, Myongji Hospital, based in the city of Goyang, South Korea, in November last year, signed a Memorandum of Understanding (MoU) with Korean IT company BICube. As the terms of the MoU, both parties would utilize DLT to develop a healthcare information exchange system and build a Hybrid Cloud platform, which blends a Public Cloud and a Private Cloud.